EPISODE · May 24, 2019 · 29 MIN
Lloyd Diamond, CEO, Pixium Vision S.A.
from Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere · host Julio G. Martinez-Clark
Lloyd is the CEO of Pixium Vision S.A., —a company with the mission to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Prior to that, he was the President & CEO of Precise Light Surgical —a company that developed a disruptive surgical resection platform that has tissue differentiating capabilities. Lloyd has 25 years of disruptive technology commercialization experience in the life science industry. Prior to Precise Light Surgical, he served as the CEO of BONESUPPORT AB, a European orthobiologic company, where he drove rapid market penetration in Europe and the US for their disruptive orthopedic scaffold. He has commercialized many other disruptive technology platforms at Kyphon and Laserscope where he served as the VP of Marketing for the Greenlight Laser system. Throughout his career, Lloyd has been Instrumental in bringing life science technologies in the major markets in Latin America, including Mexico and Brazil, and established commercial infrastructures in the region. Lloyd received a dual degree in Biochemsitry and Marketing from Florida Atlantic University and an MBA from the Thunderbird School of Global Management at ASU.
What this episode covers
Lloyd is the CEO of Pixium Vision S.A., —a company with the mission to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Prior to that, he was the President & CEO of Precise Light Surgical —a company that developed a disruptive surgical resection platform that has tissue differentiating capabilities. Lloyd has 25 years of disruptive technology commercialization experience in the life science ...
NOW PLAYING
Lloyd Diamond, CEO, Pixium Vision S.A.
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m